Early trial tests new combo to fight advanced kidney cancer
NCT ID NCT03260504
Summary
This early-stage study tested the safety and best dose of a two-drug immunotherapy combination for people with advanced kidney cancer that has spread. The trial combined pembrolizumab, a drug that helps the immune system attack cancer, with aldesleukin, which stimulates immune cells. The main goal was to see if the drugs could be given together safely and to monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.